MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA

马瑞司他治疗多形性胶质母细胞瘤或胶质肉瘤患者

• 批准号: 6303450
• 负责人: HARRY S GREENBERG
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303450
• 关键词: clinical research; clinical trials; enzyme therapy; glioblastoma multiforme; human subject; human therapy evaluation; metalloenzyme; neoplasm /cancer chemotherapy; sarcoma; tissue inhibitor of metalloproteinases

This is a multi-center, randomized, drug company initiated, placebo controlled trial of marimastat, a matrix metalloproteinase inhibitor (MMPI), in the treatment of glioblastoma multiforme or gliosarcoma inpatients who have completed surgery and radiation therapy.Multiple brain tumor centers will participate in this study where patients with receive marimastat (an inhibitor of tumor cell spread) or placebo (an inactive treatment) for their malignant glial brain tumors that have returned after surgery and radiation. Multiple brain tumor centers will participate in this study where patients with receive marimastat an inhibitor of tumor cell spread or placebo, an inactive treatment for their malignant glial brain tumors that have returned after surgery and radiation.

这是一项多中心、随机、制药公司发起的安慰剂对照试验，试验对象是基质金属蛋白酶抑制剂（MMPI）马立马司他，治疗已完成手术和放疗的多形性胶质母细胞瘤或胶质肉瘤住院患者。多个脑肿瘤中心将参与本研究，其中患者接受马立马司他（肿瘤细胞扩散的抑制剂）或安慰剂（非活性治疗）治疗他们的恶性神经胶质脑肿瘤，这些肿瘤在手术和放疗后复发。多个脑肿瘤中心将参与这项研究，其中患者接受肿瘤细胞扩散抑制剂marimastat或安慰剂，这是一种针对手术和放射后复发的恶性神经胶质脑肿瘤的非活性治疗。